# reload+after+2024-01-20 21:43:05.738965
address1§1330 Avenue of the Americas
address2§33rd Floor
city§New York
state§NY
zip§10019
country§United States
phone§646 813 4701
website§https://www.abeonatherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.
fullTimeEmployees§57
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Vishwas  Seshadri M.B.A., Ph.D.', 'age': 47, 'title': 'President, CEO & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 1021800, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joseph Walter Vazzano CPA', 'age': 39, 'title': 'Chief Financial Officer', 'yearBorn': 1984, 'fiscalYear': 2022, 'totalPay': 655168, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': "Dr. Brendan M. O'Malley J.D., Ph.D.", 'age': 54, 'title': 'Senior VP & General Counsel', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 699135, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brian  Kevany Ph.D.', 'title': 'VP, CTO & Head of Research', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gregory  Gin', 'title': 'Vice President of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Alison  Hardgrove', 'title': 'Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jon  Voss', 'age': 63, 'title': 'VP & Head of Quality', 'yearBorn': 1960, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Dmitriy  Grachev M.D., Ph.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Madhav  Vasanthavada M.B.A., Ph.D.', 'title': 'Chief Commercial Officer & Head of Business Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.281
priceToSalesTrailing12Months§39.298454
currency§USD
dateShortInterest§1702598400
forwardEps§-1.71
exchange§NCM
quoteType§EQUITY
shortName§Abeona Therapeutics Inc.
longName§Abeona Therapeutics Inc.
firstTradeDateEpochUtc§338218200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§6a7dfae4-c578-3526-bdcd-a5a90d9256dd
gmtOffSetMilliseconds§-18000000
targetHighPrice§38.0
targetLowPrice§11.0
targetMeanPrice§21.25
targetMedianPrice§18.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§6.653
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
